DocGo Inc (DCGO)vsEli Lilly and Company (LLY)
DCGO
DocGo Inc
$0.23
-2.98%
HEALTHCARE · Cap: $24.44M
LLY
Eli Lilly and Company
$1,430.13
-0.70%
HEALTHCARE · Cap: $1.26T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 29237% more annual revenue ($86.46B vs $294.72M). LLY leads profitability with a 31.9% profit margin vs -65.3%. LLY earns a higher WallStSmart Score of 74/100 (B).
DCGO
Hold36
out of 100
Grade: F
LLY
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.1%
Fair Value
$1.92
Current Price
$0.23
$1.69 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -141.9% — below average capital efficiency
Revenue declined 8.7%
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : DCGO
The strongest argument for DCGO centers on Price/Book, Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : DCGO
The primary concerns for DCGO are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses.
Key Dynamics to Monitor
DCGO profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
DCGO carries more volatility with a beta of 0.97 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 36/100), backed by strong 31.9% margins and 38.6% revenue growth. DCGO offers better value entry with a 62.1% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DocGo Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DocGo Inc. is a leading mobile healthcare service provider focused on enhancing patient accessibility and optimizing healthcare delivery through its cutting-edge logistics and telehealth solutions. The company specializes in urgent care, diagnostic testing, and health screenings, effectively addressing key healthcare challenges across diverse environments and significantly improving patient experiences. With a strong commitment to innovation and expanding access to healthcare, DocGo is well-positioned in the dynamic healthtech sector, making it an attractive investment opportunity for institutional investors interested in sustainable growth and impactful social contributions.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?